Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Tumor targeting using anti-her2 immunoliposomes.

J W Park1, D B Kirpotin, K Hong

  • 1Division of Hematology/Oncology, Department of Medicine, University of California (UCSF), 400 Parnassus Avenue, Suite A502, San Francisco, CA 94143-0324, USA. john_park@quickmail.uscf.edu

Journal of Controlled Release : Official Journal of the Controlled Release Society
|August 8, 2001
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

White Matter Injury and General Movements in High-Risk Preterm Infants.

AJNR. American journal of neuroradiology·2016
Same author

TNF-α modulates genome-wide redistribution of ΔNp63α/TAp73 and NF-κB cREL interactive binding on TP53 and AP-1 motifs to promote an oncogenic gene program in squamous cancer.

Oncogene·2016
Same author

Immunosuppressive human anti-CD83 monoclonal antibody depletion of activated dendritic cells in transplantation.

Leukemia·2015
Same author

Engineered domain-based assays to identify individual antibodies in oligoclonal combinations targeting the same protein.

Analytical biochemistry·2012
Same author

Domain-based assays of individual antibody concentrations in an oligoclonal combination targeting a single protein.

Analytical biochemistry·2011
Same author

Neutralizing human monoclonal antibodies binding multiple serotypes of botulinum neurotoxin.

Protein engineering, design & selection : PEDS·2010
Same journal

Hijacking radiotherapy-induced chemokines with self-assembled molecular decoys for glioblastoma radio-immunotherapy.

Journal of controlled release : official journal of the Controlled Release Society·2026
Same journal

A one-step surface engineering strategy based on PEG-EGCG to improve systemic delivery and survival of transplanted mesenchymal stromal cells.

Journal of controlled release : official journal of the Controlled Release Society·2026
Same journal

Selective silencing of placental anti-angiogenic factors in invasive trophoblasts via membrane-fusion divalent siRNA delivery for preeclampsia therapy.

Journal of controlled release : official journal of the Controlled Release Society·2026
Same journal

Unified inactivation-mineralization: An engineered bacterial platform for synergistic radio-immunotherapy.

Journal of controlled release : official journal of the Controlled Release Society·2026
Same journal

Loss of internal structural order induced by freezing and Lyophilization correlates with reduced in vitro activity of mRNA lipid nanoparticles.

Journal of controlled release : official journal of the Controlled Release Society·2026
Same journal

Muscle contribution in lipid nanoparticle mediated mRNA vaccine delivery and efficacy.

Journal of controlled release : official journal of the Controlled Release Society·2026
See all related articles

Anti-HER2 immunoliposomes deliver doxorubicin effectively to HER2-overexpressing cancer cells, showing potent anticancer activity and long circulation times. This targeted drug delivery method demonstrates superior efficacy over conventional treatments, paving the way for clinical trials.

Area of Science:

  • Biotechnology and Nanomedicine
  • Oncology Drug Delivery
  • Immunotherapy

Background:

  • HER2 (ErbB2) overexpression is common in several aggressive cancers, driving tumor growth and progression.
  • Targeted drug delivery systems aim to enhance therapeutic efficacy and reduce systemic toxicity.
  • Immunoliposomes (ILs) offer a strategy to combine the targeting ability of antibodies with the drug-carrying capacity of liposomes.

Purpose of the Study:

  • To develop and evaluate anti-HER2 immunoliposomes for targeted delivery of doxorubicin (dox) to HER2-overexpressing cancer cells.
  • To assess the in vitro and in vivo efficacy, pharmacokinetics, and biodistribution of anti-HER2 ILs.
  • To elucidate the mechanism of intracellular drug delivery and its correlation with antitumor activity.

Main Methods:

Related Experiment Videos

  • Construction of anti-HER2 immunoliposomes using a modular strategy with antibody fragments and optimized liposome formulations.
  • In vitro evaluation of binding, internalization, and drug delivery in HER2-overexpressing cells using microscopy and fluorescent probes.
  • In vivo studies in xenograft models to assess pharmacokinetics, tumor localization, antitumor activity, and compare with control treatments.

Main Results:

  • Anti-HER2 ILs demonstrated efficient binding and internalization in HER2-overexpressing cells, leading to up to 700-fold greater drug uptake compared to non-targeted liposomes.
  • In vivo, anti-HER2 ILs exhibited long circulation times and potent anticancer activity in HER2-overexpressing xenograft models, significantly outperforming free drug, liposomal drug, and antibody treatments.
  • Histologic studies revealed efficient intracellular drug delivery into tumor cells via receptor-mediated endocytosis for anti-HER2 ILs, contrasting with the stromal accumulation of non-targeted liposomes.

Conclusions:

  • Anti-HER2 immunoliposomes represent a promising technology for targeted cancer therapy, achieving superior antitumor efficacy through receptor-mediated intracellular drug delivery.
  • The optimized anti-HER2 ILs-dox construct, utilizing scFv F5 and liposomal doxorubicin, is suitable for clinical development.
  • This immunoliposome strategy may offer an effective approach for delivering anthracycline chemotherapy to HER2-overexpressing cancers while potentially mitigating cardiotoxicity.